Blog
RSS FeedPosted by Michael Wonder on 06 Aug 2021
Updated financial estimates workbook
6 August 2021 - An updated version of the Utilisation and Cost Model workbook is now available to support PBAC submissions. ...
Posted by Michael Wonder on 04 May 2020
Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy
1 May 2020 - The reimbursement of the immune checkpoint inhibitors is challenging. ...
Posted by Michael Wonder on 30 Mar 2020
Updated Financial Estimates workbook and manual
30 March 2020 - An updated version of the Utilisation and Cost Model workbook and a user manual are now available ...
Posted by Michael Wonder on 20 Feb 2018
The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges
20 February 2018 - Good practices for budget impact analysis have been increasingly developed since the year 2000. ...
Posted by Michael Wonder on 17 Dec 2017
Pharmaceutical Benefits Advisory Committee recommendations in Australia
16 December 2017 - The aim of this study was to examine submissions made to the PBAC and assess whether the ...
Posted by Michael Wonder on 11 Oct 2017
Obesity related diseases expected to cost Australia $21 billion
11 October 2017 - Without action on obesity, the economic burden of treating obesity related diseases is estimated to rise from ...
Posted by Michael Wonder on 26 Sep 2017
Final budget outcomes reveal industry efforts to take pressure off PBS
26 September 2017 - The Final Budget Outcome papers released today reveal the enormous efforts of the members of Medicines ...
Posted by Michael Wonder on 05 Dec 2016
Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months
5 December 2016 - Hepatitis C medications approved in March this year have already topped the list of Australia's most ...